Belluscura plc
("Belluscura" or the "Company")
Director / PDMR Shareholding
The Company was notified that on 7 October 2021 Chief Financial Officer Tony Dyer had sold 90,000 Ordinary Shares of 1 pence each in the Company ("Shares") at 88.0 pence per share and that at the same time his personal SIPP had purchased 90,000 shares at 88.05p per share.
Mr Dyer's total interest in the Company remains at 636,941 shares, 0.56% of the Company's issued share capital.
For further information please contact:
|
Belluscura plc |
|
|
Robert Rauker, Chief Executive Officer |
via Walbrook PR |
|
Anthony Dyer, Chief Financial Officer |
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin |
|
|
|
|
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
|
James Serjeant / Nicholas Chambers |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com |
|
Paul McManus / Sam Allen |
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
Belluscura is listed on the AIM market of the London Stock Exchange (AIM: BELL).
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Anthony Dyer |
||||
|
2 |
Reason for notification |
|||||
|
a) |
Position / status |
Chief Financial Officer |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Belluscura plc |
||||
|
b) |
LEI |
213800BRJQZE56XBPW94 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 each in Belluscura plc ISIN : GB00BD3B8Z11 |
||||
|
b) |
Nature of the transaction |
Sale of shares and immediate purchase into personal SIPP |
||||
|
c) |
Price(s) and volumes(s) |
|
||||
|
d) |
Aggregated information |
n/a |
||||
|
e) |
Date of the transaction |
7 October 2021 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
